Clin2
NCT06351592Possibly a fitRecruiting

Study of ALN-SOD for ALS with SOD1 gene mutation

Amyotrophic Lateral Sclerosis (ALS)Mutation in the Superoxide Dismutase-1 (SOD1) Gene

Part of Brain & nervous system, Hormones & metabolism clinical trials.

This trial tests an experimental drug called ALN-SOD for people with ALS caused by a specific genetic mutation in the SOD1 gene. The goal is to see if it is safe and can help slow the disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
54 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have ALS and a known SOD1 gene mutation
  • Your lung function (SVC) is at least 50% of normal for your age and height
  • Your BMI is 35 or less
  • If you take riluzole or edaravone, the dose must be stable for at least 4 weeks before starting
  • You have not had a tracheostomy or treatment with tofersen in the last 6 months

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07369076Recruiting· Phase 1/Phase 2
Testing NB-4746 for people with ALS

This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.

Concord, New South Wales
NCT06849609Recruiting· Early Phase 1
Gene therapy VGN-R13 for ALS safety and tolerability

This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.

Wuhan, Hubei
NCT07118319Recruiting· Phase 1
Stem cell therapy safety trial for ALS

This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.

Beijing, Beijing Municipality
NCT06126315Recruiting· Phase 2/Phase 3
Testing acetyl-L-carnitine in early ALS

This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.

Sydney
NCT06556394Recruiting· Phase 1
Testing RAG-17 for ALS with SOD1 gene mutation

This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.

Beijing
NCT07077668Not yet recruiting· Early Phase 1
RAG-17 extended study for ALS with SOD1 mutation

This trial tests a new treatment called RAG-17 for people with ALS who have a specific genetic change (SOD1 mutation). The goal is to see if it can slow the disease.

Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.